Together, our findings provide the first evidence implicating aberrant CDK5 function in fibrosis in SSc, and suggest that pharmacological targeting of the CDK5 pathway may represent a potential therapeutic strategy for fibrosis. Here, CDK5 is linked to systemic sclerosis.